| Jun 28 |
PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
|
| Jun 28 |
PTC drops as EU panel declines to recommend Translarna marketing renewal
|
| Jun 28 |
CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
|
| Jun 24 |
PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock?
|
| Jun 20 |
PTC Therapeutics says FDA lifted partial hold on Huntington's disease program
|
| Jun 20 |
PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder
|
| Jun 20 |
FDA lifts hold on PTC Huntington’s disease trial
|
| Jun 20 |
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients
|
| May 29 |
PTC Therapeutics to Participate at Upcoming Investor Conference
|
| May 28 |
PTC Therapeutics announces validation of Sepiapterin European MAA
|
